


## Financial Tear Sheet

### Company Profile

Merus discovers and develops differentiated therapeutics aimed at substantially prolonging the lives of cancer patients. It is our strategy to use the power of bispecific antibody engineering and advanced screening technologies to develop biopharmaceuticals that engage the power of the immune system to kill tumor cells.

### Share Performance

MRUS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$12.92
Change (%)	▼ 0.34 (2.56%)
Volume	42,520
52 Week Low	\$11.00
Market Cap	\$301,460,239
Rolling EPS	-2.07
PE Ratio	0
Shares Outstanding	22,734,558
Data as of 01/17/19 12:29 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

### News & Events

Date	Title
01/07/19	Merus Announces IND Clearance for MCLA-145
01/02/19	Merus Announces Strategic Collaboration with Betta

There are currently no events scheduled.

Pharmaceuticals to Develop and Commercialize MCLA-129 in China

12/27/18 Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update

## SEC Filings

Filing Date	Form
01/03/19	SC 13G
01/02/19	D
01/02/19	6-K
12/27/18	6-K

## Supervisory Board

Ton Logtenberg, Ph.D	CEO, Executive Director
Russell Greig	Chairman, Non-Executive Director
Anand Mehra, M.D.	Non-Executive Director
John de Koning, Ph.D.	Non-Executive Director
Gregory Perry	Non-Executive Director
Mark Iwicki	Non- Executive Director
Len Kanavy	Non-Executive Director

## Primary IR Contact

Kimberly Minarovich  
Argot Partners  
Phone: 1 212-600-1902  
E-mail: [kimberly@argotpartners.com](mailto:kimberly@argotpartners.com)

## Management Board

Ton Logtenberg, Ph.D	CEO
Shelley Margetson	CFO